How would you approach a T3N1M0 mid rectal cancer that is MMR deficient?
Answer from: Medical Oncologist at Academic Institution
About 2.7% of rectal adenocarcinoma are mismatch repair deficient (dMMR) (Papke Jr. et al., PMID 36322852) and locally advanced dMMR rectal cancers have a great response to immunotherapy. Six months of single agent Dostarlimab led to 100% complete clinical response in the phase 2 study including 14 ...
Comments
Radiation Oncologist at West Virginia University Not sure there will be a sea change in management ...
Not sure there will be a sea change in management ...